Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GDUFA II Reviews Start Strong With High First-Cycle Approval Rate

Executive Summary

Performance numbers are likely to fluctuate over the course of the program, but the rate of first-cycle approvals during the first month of the new user fee program is more than double the rate during the last year of the old iteration. 

Advertisement

Related Content

Lack Of Priority? No ANDAs Approved Using Expedited Pathway In FY 2018
Lack Of Priority? No ANDAs Approved Using Expedited Pathway In FY 2018
US FDA's Generics Program Reaches 'Steady State' Milestone
US FDA's Generics Program Reaches 'Steady State' Milestone
ANDA Amendments Cannot Get Mid-Review Communications Like Full Applications - FDA
FDA Contradicts AAM's Generic Market Consolidation Argument
New ANDA Review Pathways: Should You Be A Priority Or Expedited?
Gottlieb Places Drug Pricing Out Front In First Speech To US FDA Staff
ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?

Topics

Advertisement
UsernamePublicRestriction

Register

PS122073

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel